Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections

Parasites and Vectors

Volumn 7, Issue 1, 2014, Pages

  Turner, Hugo C ^a   Walker, Martin ^a   Churcher, Thomas S ^a   Basáñez, María Gloria ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Africa; Control programmes; DALY; Disease burden; Epidemiology; Ivermectin; Mathematical modelling; Morbidity; Mortality; Neglected tropical diseases; Onchocerciasis; River blindness

Indexed keywords

IVERMECTIN; ANTHELMINTIC AGENT;

ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; MATHEMATICAL MODEL; MEDICATION COMPLIANCE; MORBIDITY; MORTALITY; ONCHOCERCIASIS; PATIENT COMPLIANCE; SINGLE DRUG DOSE; SKIN INFECTION; VISUAL ACUITY; VISUAL FIELD; VISUAL IMPAIRMENT; AFRICA; BIOLOGICAL MODEL; BLINDNESS; ONCHOCERCIASIS, OCULAR; PARASITOLOGY; TIME FACTOR;

ONCHOCERCA VOLVULUS;

AFRICA; ANTHELMINTICS; BLINDNESS; HUMANS; IVERMECTIN; MODELS, BIOLOGICAL; ONCHOCERCIASIS, OCULAR; TIME FACTORS;

EID: 84902118155     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/1756-3305-7-241     Document Type: Article

References (92)

1. Human onchocerciasis-an overview of the disease. Duke BOL, Acta Leiden 1990 59 1-2 9 24 2198761
2. The reproductive lifespan of Onchocerca volvulus in West African savanna. Plaisier AP, van Oortmarssen GJ, Remme JHF, Habbema JD, Acta Trop 1991 48 4 271 284 10.1016/0001-706X(91)90015-C 1674401
3. Chapter 39: Onchocerciasis. Bradley JE, Whitworth J, Basáñez MG, Topley and Wilson's Microbiology and Microbial Infections London: Edward Arnold Publishers Ltd, Wakelin D, Cox F, Despommier D, Gillespie S, 10 2005 781 801
4. Pathogenesis of onchocercal keratitis (River blindness). Hall LR, Pearlman E, Clin Microbiol Rev 1999 12 3 445 453 10398675 (Pubitemid 29330139)
5. Onchocerciasis: the role of Wolbachia bacterial endosymbionts in parasite biology, disease pathogenesis, and treatment. Tamarozzi F, Halliday A, Gentil K, Hoerauf A, Pearlman E, Taylor MJ, Clin Microbiol Rev 2011 24 3 459 468 10.1128/CMR.00057-10 21734243
6. Pathogenesis and host responses in human onchocerciasis: impact of Onchocerca filariae and Wolbachia endobacteria. Brattig NW, Microbes Infect 2004 6 1 113 128 10.1016/j.micinf.2003.11.003 14738900 (Pubitemid 38114828)
7. A clinical classification and grading system of the cutaneous changes in onchocerciasis. Murdoch ME, Hay RJ, Mackenzie CD, Williams JF, Ghalib HW, Cousens S, Abiose A, Jones BR, Br J Dermatol 1993 129 3 260 269 10.1111/j.1365-2133.1993.tb11844.x 8286222 (Pubitemid 23283996)
8. Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study. Little MP, Breitling LP, Basáñez MG, Alley ES, Boatin BA, Lancet 2004 363 9420 1514 1521 10.1016/S0140-6736(04)16151-5 15135599 (Pubitemid 38596829)
9. Density-dependent mortality of the human host in onchocerciasis: relationships between microfilarial load and excess mortality. Walker M, Little MP, Wagner KS, Soumbey-Alley EW, Boatin BA, Basáñez MG, PLoS Negl Trop Dis 2012 6 3 1578 10.1371/journal.pntd.0001578 22479660
10. Relationships between mortality, visual acuity and microfilarial load in the area of the Onchocerciasis Control Programme. Kirkwood B, Smith P, Marshall T, Prost A, Trans R Soc Trop Med Hyg 1983 77 6 862 868 10.1016/0035-9203(83) 90308-5 6665841
11. Control of onchocerciasis. Boatin BA, Richards FO Jr, Adv Parasitol 2006 61 349 394 16735169 (Pubitemid 43792518)
12. River Blindness: a success story under threat? Basáñez MG, Pion SDS, Churcher TS, Breitling LP, Little MP, Boussinesq M, PLoS Med 2006 3 9 371 10.1371/journal.pmed.0030371 17002504 (Pubitemid 44455248)
13. The embryogenesis of Onchocerca volvulus over the first year after a single dose of ivermectin. Duke BOL, Zea-Flores G, Munoz B, Trop Med Parasitol 1991 42 3 175 180 1801140
14. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Basáñez MG, Pion SDS, Boakes E, Filipe JAN, Churcher TS, Boussinesq M, Lancet Infect Dis 2008 8 5 310 322 10.1016/S1473-3099(08)70099-9 18471776 (Pubitemid 351615758)
15. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. Diawara L, Traoré MO, Badji A, Bissan Y, Doumbia K, Goita SF, Konaté L, Mounkoro K, Sarr MD, Seck AF, Toé L, Tourée S, Remme JHF, PLoS Negl Trop Dis 2009 3 7 497 10.1371/journal.pntd.0000497 19621091
16. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, Doumbia K, Goita SF, Konate L, Mounkoro K, Seck AF, Toé L, Tourée S, Remme JHF, PLoS Negl Trop Dis 2012 6 9 1825 10.1371/journal.pntd.0001825 23029586
17. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control. Tekle A, Elhassan E, Isiyaku S, Amazigo U, Bush S, Noma M, Cousens S, Abiose A, Remme JHF, Parasit Vectors 2012 5 1 28 10.1186/1756-3305-5-28 22313631
18. African Programme for Onchocerciasis Control, 18th Session of the Joint Action Forum Bujumbura, Burundi 2012 http://www.who.int/apoc/media/Journal-du- FAC-day-4-Anglais.pdf
19. London Declaration on Neglected Tropical Diseases, Uniting to combat Neglected Tropical Diseases. Ending the neglect and reaching 2020 goals London 2012 http://unitingtocombatntds.org/downloads/press/ntd-event-london- declaration-on-ntds.pdf
20. World Health Organization, Accelerating work to overcome the global impact of neglected tropical diseases- A roadmap for implementation World Health Organization 2012 http://www.who.int/neglected-diseases/NTD-RoadMap-2012- Fullversion.pdf
21. Population biology of human onchocerciasis. Basáñez MG, Boussinesq M, Philos Trans R Soc Lond B Biol Sci 1999 354 1384 809 826 10.1098/rstb.1999.0433 10365406 (Pubitemid 29365629)
22. Human infection patterns and heterogeneous exposure in river blindness. Filipe JAN, Boussinesq M, Renz A, Collins RC, Vivas-Martinez S, Grillet ME, Little MP, Basáñez MG, Proc Natl Acad Sci U S A 2005 102 42 15265 15270 10.1073/pnas.0502659102 16217028 (Pubitemid 41513370)
23. Uncertainty surrounding projections of the long-term impact of ivermectin treatment for human onchocerciasis. Turner HC, Churcher TS, Walker M, Osei-Atweneboana MY, Prichard RK, Basáñez MG, PLoS Negl Trop Dis 2013 7 4 2169 10.1371/journal.pntd.0002169 23634234
24. Density dependence and the spread of anthelmintic resistance. Churcher TS, Basáñez MG, Evolution 2008 62 3 528 537 10.1111/j.1558-5646. 2007.00290.x 17983465 (Pubitemid 351348245)
25. Habbema D, Stolk W, Veerman L, de Vlas S, A rapid health impact assessment of APOC: exeutive summary & technical report APOC 2007 http://www.who.int/apoc/publications/APOC%20rapid%20HIA-final%20report-def.pdf
26. African Programme for Onchocerciasis Control 1995-2015: model-estimated health impact and cost. Coffeng LE, Stolk WA, Zouré HGM, Veerman JL, Agblewonu KB, Murdoch ME, Noma M, Fobi G, Richardus JH, Bundy DAP, Habbema D, de Vlas SJ, Amazigo UV, PLoS Negl Trop Dis 2013 7 1 2032 10.1371/journal.pntd. 0002032 23383355
27. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, et al. Lancet 2012 380 9859 2197 2223 10.1016/S0140-6736(12)61689-4 23245608
28. Can ivermectin mass treatments eliminate onchocerciasis in Africa? Winnen M, Plaisier AP, Alley ES, Nagelkerke NJ, van Oortmarssen G, Boatin BA, Habbema JD, Bull World Health Organ 2002 80 5 384 391 12077614
29. Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa. Plaisier AP, Alley ES, Boatin BA, Van Oortmarssen GJ, Remme JHF, De Vlas SJ, Bonneux L, Habbema JD, J Infect Dis 1995 172 1 204 210 10.1093/infdis/172.1.204 7797912
30. Rates of microfilarial production by Onchocerca volvulus are not cumulatively reduced by multiple ivermectin treatments. Bottomley C, Isham V, Collins RC, Basáñez MG, Parasitology 2008 135 13 1571 1581 10.1017/S0031182008000425 18831801
31. Dynamics of Onchocerca volvulus microfilarial densities after ivermectin treatment in an ivermectin-naïve and a multi-treated population from Cameroon. Pion SDS, Nana-Djeunga HC, Kamgno J, Tendongfor N, Wanji S, Njiokou F, Prichard RK, Boussinesq M, PLoS Negl Trop Dis 2013 7 2 2084 10.1371/journal.pntd.0002084 23469307
32. A research agenda for helminth diseases of humans: modelling for control and elimination. Basáñez M-G, McCarthy JS, French MD, Yang G-J, Walker M, Gambhir M, Prichard RK, Churcher TS, PLoS Negl Trop Dis 2012 6 4 1548 10.1371/journal.pntd.0001548 22545162
33. Studies on onchocerciasis in the United Cameroon Republic II. Comparison of onchocerciasis in rain-forest and Sudan-savanna. Anderson J, Fuglsang H, Hamilton PJS, De C, Marshall TF, Trans R Soc Trop Med Hyg 1974 68 3 209 222 10.1016/0035-9203(74)90117-5 4421167
34. Studies on the dynamics of transmission of onchocerciasis in a Sudan-savanna area of North Cameroon IV. The different exposure to Simulium bites and transmission of boys and girls and men and women, and the resulting manifestations of onchocerciasis. Renz A, Fuglsang H, Anderson J, Ann Trop Med Parasitol 1987 81 3 253 262 3662667 (Pubitemid 17120314)
35. Le diagnostique de l'onchocercose. Revue critique des méthodes en usage. Prost A, Prod'hon J, Méd Trop Mars 1978 38 519 532 (Pubitemid 9093704)
36. Onchocerciasis: the pre-control association between prevalence of palpable nodules and skin microfilariae. Coffeng LE, Pion SD, O'Hanlon S, Cousens S, Abiose AO, Fischer PU, Remme JHF, Dadzie KY, Murdoch ME, de Vlas SJ, Basáñez MG, Stolk WA, Boussinesq M, PLoS Negl Trop Dis 2013 7 4 2168 10.1371/journal.pntd.0002168 23593528
37. A force-of-infection model for onchocerciasis and its applications in the epidemiological evaluation of the Onchocerciasis Control Programme in the Volta River basin area. Remme JHF, Ba O, Dadzie KY, Karam M, Bull World Health Organ 1986 64 5 667 681 3492300 (Pubitemid 17208606)
38. Treatment of human onchocerciasis: the efficacy of ivermectin on the parasite. Schulz-Key H, Kläger S, Awadzi K, Diallo S, Greene BM, Larivière M, Aziz MA, Trop Med Parasitol (Suppl II) 1985 36 20
39. Histological examination of onchocercomata after therapy with ivermectin. Albiez EJ, Walter G, Kaiser A, Ranque P, Newland HS, White AT, Greene BM, Taylor HR, Büttner DW, Trop Med Int Health 1988 39 2 93 99
40. The effects of long-term community level treament with ivermectin (Mectizan) on adult Onchocerca volvulus in Latin America. Cupp EW, Duke BOL, Mackenzie CD, Guzmán JR, Vieira JC, Mendez-Galvan J, Castro J, Richards FO, Sauerbrey M, Dominguez A, Eversole RR, Cupp MS, Am J Trop Med Hyg 2004 71 5 602 607 15569792 (Pubitemid 39601159)
41. Evidence for macrofilaricidal activity of ivermectin against female Onchocerca volvulus: further analysis of a clinical trial in the Republic of Cameroon indicating two distinct killing mechanisms. Duke BOL, Parasitology 2005 130 4 447 453 10.1017/S0031182004006766 15830819 (Pubitemid 40516295)
42. A community trial of ivermectin for onchocerciasis in Sierra Leone: compliance and parasitological profiles after three and a half years of intervention. Whitworth JAG, Downham MD, Lahai G, Maude GH, Trop Med Int Healt 1996 1 1 52 58 10.1046/j.1365-3156.1996.d01-3.x
43. Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Gardon J, Boussinesq M, Kamgno J, Gardon-Wendel N, Demanga-Ngangue, Duke BOL, Lancet 2002 360 9328 203 210 10.1016/S0140-6736(02)09456-4 12133654 (Pubitemid 34804647)
44. Ivermectin: reduction in prevalence and infection intensity of Onchocerca volvulus following biannual treatments in five Guatemalan communities. Collins RC, Gonzales-Peralta C, Castro J, Zea-Flores G, Cupp MS, Richards FO, Cupp EW, Am J Trop Med Hyg 1992 47 2 156 169 1503185
45. The impact of five years of annual ivermectin treatment on skin microfilarial loads in the onchocerciasis focus of Asubende, Ghana. Alley ES, Plaisier AP, Boatin BA, Dadzie KY, Remme JHF, Zerbo G, Samba EM, Trans R Soc Trop Med Hyg 1994 88 5 581 584 10.1016/0035-9203(94)90172-4 7992347 (Pubitemid 24325217)
46. Incidence of blindness during the Onchocerciasis control programme in western Africa, 1971-2002. Little MP, Basáñez MG, Breitling LP, Boatin BA, Alley ES, J Infect Dis 2004 189 10 1932 1941 10.1086/383326 15122532 (Pubitemid 38657231)
47. Remme JHF, Global burden of onchocerciasis in 1990 World Health Organization 2004 http://www.who.int/healthinfo/global-burden-disease/ Onchocerciasis%201990.pdf
48. Shibuya K, Bernard C, Ezzati M, Mathers CD, Global burden of onchocerciasis in the year 2000: Summary of methods and data sources World Health Organization 2006 http://www.who.int/healthinfo/statistics/bod- onchocerciasis.pdf
49. Ivermectin for onchocercal eye disease (river blindness). Ejere H, Schwartz E, Wormald R, Evans JR, Cochrane Database Syst Rev 2012 8 CD002219
50. Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa. Murdoch ME, Asuzu MC, Hagan M, Makunde WH, Ngoumou P, Ogbuagu KF, Okello D, Ozoh G, Remme JHF, Ann Trop Med Parasitol 2002 96 3 283 296 10.1179/000349802125000826 12061975 (Pubitemid 34548049)
51. Onchodermal skin disease in a hyperendemic onchocerciasis focus in western Uganda. Kipp W, Bamhuhiiga J, Am J Trop Med Hyg 2002 67 5 475 479 12479547 (Pubitemid 35403161)
52. Severe onchocercal dermatitis in the Ethiopian border region of Sudan. Ghalib HW, MacKenzie CD, Kron MA, Williams JF, el Khalifa M, el Sheikh H, Ann Trop Med Parasitol 1987 81 4 405 419 3446029 (Pubitemid 17145043)
53. The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial. Brieger WR, Awedoba AK, Eneanya CI, Hagan M, Ogbuagu KF, Okello DO, Ososanya OO, Ovuga EB, Noma M, Kale OO, Burnham GM, Remme JHF, Trop Med Int Health 1998 3 12 951 961 10.1046/j.1365-3156.1998.00339.x 9892280 (Pubitemid 29029401)
54. Latency period in onchocerciasis. Prost A, Bull World Health Organ 1980 58 6 923 925 In French 6971189
55. World Health Organization, Global Burden of Disease update 2004: disability weights for diseases and conditions World Health Organization 2004 http://www.who.int/healthinfo/global-burden-disease/GBD2004-DisabilityWeights. pdf
56. World Health Organization, Making choices in health: WHO guide to cost-effectiveness analysis World Health Organization 2003 [ http://www.who.int/choice/publications/p-2003-generalised-cea.pdf ]
57. African Programme for Onchocerciasis Control, Conceptual and operational framework of onchocerciasis elimination with ivermectin treatment WHO/APOC 2010 http://www.who.int/apoc/oncho-elimination-report-english.pdf
58. Ocular onchocerciasis and intensity of infection in the community. I. West African savanna. Remme JHF, Dadzie KY, Rolland A, Thylefors B, Trop Med Parasitol 1989 40 3 340 347 2617045 (Pubitemid 19251010)
59. Cost-effectiveness of blindness prevention by the Onchocerciasis Control Programme in Upper Volta. Prost A, Prescott N, Bull World Health Organ 1984 62 5 795 802 6439428 (Pubitemid 15223587)
60. Eliminating onchocerciasis after 14 years of vector control: a proved strategy. Hougard JM, Alley ES, Yaméogo L, Dadzie KY, Boatin BA, J Infect Dis 2001 184 4 497 503 10.1086/322789 11471108 (Pubitemid 32718514)
61. Control of onchocerciasis in Africa: threshold shifts, breakpoints and rules for elimination. Duerr HP, Raddatz G, Eichner M, Int J Parasitol 2011 41 5 581 589 10.1016/j.ijpara.2010.12.009 21255577
62. Onchocerca-Simulium interactions and the population and evolutionary biology of Onchocerca volvulus. Basáñez MG, Churcher TS, Grillet ME, Adv Parasitol 2009 68 263 313 19289198
63. Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa. Borsboom GJJM, Boatin BA, Nagelkerke NJD, Agoua H, Akpoboua KLB, Alley EW, Bissan Y, Renz A, Yameogo L, Remme JHF, Habbema JD, Filaria J 2003 2 1 8 10.1186/1475-2883-2-8 12769825 (Pubitemid 38751363)
64. Transmission of Onchocerca volvulus continues in Nyagak-Bondo focus of northwestern Uganda after 18 years of a single dose of annual treatment with ivermectin. Katabarwa MN, Lakwo T, Habomugisha P, Agunyo S, Byamukama E, Oguttu D, Tukesiga E, Unoba D, Dramuke P, Onapa A, Tukahebwa EM, Lwamafa D, Walsh F, Unnasch TR, Am J Trop Med Hyg 2013 89 2 293 300 10.4269/ajtmh.13-0037 23690555
65. Seventeen years of annual distribution of ivermectin has not interrupted onchocerciasis transmission in North Region. Katabarwa MN, Eyamba A, Nwane P, Enyong P, Yaya S, Baldiagai J, Madi TK, Yougouda A, Andze GO, Richards FO, Cameroon Am J Trop Med Hyg 2011 85 6 1041 1049 10.4269/ajtmh.2011.11-0333
66. Fifteen years of annual mass treatment of onchocerciasis with ivermectin have not interrupted transmission in the West Region of Cameroon. Katabarwa MN, Eyamba A, Nwane P, Enyong P, Kamgno J, Kuete T, Yaya S, Aboutou R, Mukenge L, Kafando C, Siaka C, Mkpouwoueiko S, Ngangue D, Biholong BD, Andze GO, J Parasitol Res 2013 2013 420928 23691275
67. Lymphatic filariasis and onchocerciasis. Taylor MJ, Hoerauf A, Bockarie M, Lancet 2010 376 9747 1175 1185 10.1016/S0140-6736(10)60586-7 20739055
68. A three-year follow-up of ocular onchocerciasis in an area of vector control. Thylefors B, Tonjum AM, Bull World Health Organ 1980 58 1 107 112 6966541 (Pubitemid 10013260)
69. The effect of 7-8 years of vector control on the evolution of ocular onchocerciasis in West African savanna. Dadzie KY, Remme JHF, Rolland A, Thylefors B, Trop Med Parasitol 1986 37 3 263 270 3787122 (Pubitemid 16002917)
70. A longitudinal study of impact of repeated mass ivermectin treatment on clinical manifestations of onchocerciasis in Imo State. Emukah EC, Osuoha E, Miri ES, Onyenama J, Amazigo U, Obijuru C, Osuji N, Ekeanyanwu J, Amadiegwu S, Korve K, Richards FO, Nigeria Am J Trop Med Hyg 2004 70 5 556 561 (Pubitemid 38658153)
71. Tropical diseases targeted for elimination: Chagas disease, lymphatic filariasis, onchocerciasis, and leprosy. Remme JHF, Feenstra P, Lever PR, Medici AC, Morel CM, Disease Control Priorities in Developing Countries New York: Oxford University Press, Jamison DT, Breman JG, Measham AR, 2006 433 449
72. The African Programme for Onchocerciasis Control: impact on onchocercal skin disease. Ozoh GA, Murdoch ME, Bissek AC, Hagan M, Ogbuagu K, Shamad M, Braide EI, Boussinesq M, Noma MM, Murdoch IE, Sékétéli A, Amazigo UV, Trop Med Int Health 2011 16 7 875 883 10.1111/j.1365-3156.2011. 02783.x 21481109
73. Maintaining compliance to ivermectin in communities in two West African countries. Whitworth JA, Alexander ND, Seed P, Thomas W, Abiose A, Jones BR, Health Policy Plan 1996 11 3 299 307 10.1093/heapol/11.3.299 10160375 (Pubitemid 26306219)
74. Ivermectin does not reduce the burden of itching in an onchocerciasis endemic community. Whitworth JA, Luty AJ, Maude GH, Morgan D, Downham MD, Taylor DW, Trans R Soc Trop Med Hyg 1992 86 3 281 283 10.1016/0035-9203(92)90309-Z 1412653
75. A community-based trial of ivermectin for onchocerciasis control in the forest of southwestern Cameroon: clinical and parasitologic findings after three treatments. Somo RM, Ngosso A, Dinga JS, Enyong PA, Fobi G, Am J Trop Med Hyg 1993 48 1 9 13 8427394 (Pubitemid 23072557)
76. Clinical and parasitological responses after up to 6.5 years of ivermectin treatment for onchocerciasis. Whitworth JA, Maude GH, Downham MD, Trop Med Int Health 1996 1 6 786 793 8980590 (Pubitemid 27010558)
77. The effect of 5 years of annual treatment with ivermectin (Mectizan) on the prevalence and morbidity of onchocerciasis in the village of Gami in the Central African Republic. Kennedy MH, Bertocchi I, Hopkins AD, Meredith SE, Ann Trop Med Parasitol 2002 96 3 297 307 10.1179/000349802125000736 12061976 (Pubitemid 34548050)
78. Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria. Brieger WR, Okeibunor JC, Abiose AO, Wanji S, Elhassan E, Ndyomugyenyi R, Amazigo UV, Parasit Vectors 2011 4 152 10.1186/1756-3305-4-152 21794139
79. Characteristics of persons who complied with and failed to comply with annual ivermectin treatment. Brieger WR, Okeibunor JC, Abiose AO, Ndyomugyenyi R, Wanji S, Elhassan E, Amazigo UV, Trop Med Int Health 2012 17 7 920 930 10.1111/j.1365-3156.2012.03007.x 22575028
80. Studies on factors influencing the transmission of onchocerciasis. VII. A comparison of the Onchocerca volvulus transmission potentials of Simulium damnosum populations in four Cameroon rain-forest villages and the pattern of onchocerciasis associated therewith. Duke BOL, Moore PJ, Anderson J, Ann Trop Med Parasitol 1972 66 2 219 234 5038247
81. Ocular onchocerciasis and intensity of infection in the community. II. West African rainforest foci of the vector Simulium yahense. Dadzie KY, Remme JHF, Rolland A, Thylefors B, Trop Med Parasitol 1989 40 3 348 354 2559472 (Pubitemid 19251011)
82. Indices of onchocerciasis transmission by different members of the Simulium damnosum complex conflict with the paradigm of forest and savanna parasite strains. Cheke RA, Garms R, Acta Trop 2013 125 1 43 52 10.1016/j.actatropica.2012.09.002 22995985
83. Relationship between onchocerciasis and epilepsy: a matched case-control study in the Mbam Valley, Republic of Cameroon. Boussinesq M, Pion SDS, Demanga-Ngangue, Kamgno J, Trans R Soc Trop Med Hyg 2002 96 5 537 541 10.1016/S0035-9203(02)90433-5 12474484 (Pubitemid 35386230)
84. Epilepsy in onchocerciasis endemic areas: systematic review and meta-analysis of population-based surveys. Pion SDS, Kaiser C, Boutros-Toni F, Cournil A, Taylor MM, Meredith SE, Stufe A, Bertocchi I, Kipp W, Preux PM, Boussinesq M, PLoS Negl Trop Dis 2009 3 6 461 10.1371/journal.pntd.0000461 19529767
85. The Nakalanga syndrome in Kabarole District, Western Uganda. Kipp W, Burnham G, Bamuhiiga J, Leichsenring M, Am J Trop Med Hyg 1996 54 1 80 83 8651377 (Pubitemid 26045740)
86. Epilepsy, retarded growth and onchocerciasis, in two areas of different endemicity of onchocerciasis in Burundi. Newell ED, Vyungimana F, Bradley JE, Trans R Soc Trop Med Hyg 1997 91 5 525 527 10.1016/S0035-9203(97)90009-2 9463656 (Pubitemid 27478635)
87. Paradigm lost: how parasite control may alter pattern and process in human helminthiases. Basáñez MG, French MD, Walker M, Churcher TS, Trends Parasitol 2012 28 4 161 171 10.1016/j.pt.2012.02.004 22425708
88. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). Zouré HGM, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, Remme JHF, PLoS Negl Trop Dis 2011 5 6 1210 10.1371/journal.pntd.0001210 21738809
89. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M, Lancet 1997 350 9070 18 22 10.1016/S0140-6736(96)11094-1 9217715 (Pubitemid 27279765)
90. The cost of annual versus biannual community-directed treatment with Ivermectin: Ghana as a case study. Turner HC, Osei-Atweneboana MY, Walker M, Tettevi EJ, Churcher TS, Asiedu O, Biritwum N-K, Basáñez MG, PLoS Negl Trop Dis 2013 7 9 2452 10.1371/journal.pntd.0002452 24069497
91. The impact of ivermectin treatment alone and when in parallel with Simulium neavei elimination on onchocerciasis in Uganda. Ndyomugyenyi R, Tukesiga E, Büttner DW, Garms R, Trop Med Int Health 2004 9 8 882 886 10.1111/j.1365-3156.2004.01283.x 15303993 (Pubitemid 39120146)
92. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Hoerauf A, Specht S, Büttner M, Pfarr K, Mand S, Fimmers R, Marfo-Debrekyei Y, Konadu P, Debrah AY, Bandi C, Brattig N, Albers A, Larbi J, Batsa L, Taylor MJ, Adjei O, Büttner DW, Med Microbiol Immunol 2008 197 3 295 311 10.1007/s00430-007-0062-1 17999080